Europe Multiple Myeloma Therapeutics Market Research Report - Segmented By Treatment Type, Drug Type & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2024 to 2029)

Updated On: January, 2024
ID: 801
Pages: 145

Europe Multiple Myeloma Therapeutics Market Size (2023 to 2028)

The Europe Multiple Myeloma Therapeutics Market was worth USD 2.07 billion in 2023 and is estimated to be growing at a CAGR of 4.58%, to reach USD 2.59 billion by 2028.

The growing number of improvements in the healthcare industry and the rising prevalence of hematological cancer are a few of the key factors driving the multiple myeloma therapeutics market in the European region. Specific genetic defects cause multiple myeloma. The disease is treated with medications that modify the immune system and help improve the efficacy of chemotherapies, radiation therapies, stem cell transplants, and platelet transfusions. Furthermore, increasing consumer awareness of the benefits of biologic treatment medications, which use the body's immune system to locate and target myeloma cells, boosts the market growth. Various technical advancements, such as the discovery of microRNA therapies and nanomedicines for treating multiple myeloma, are also working as growth stimulants. The substantial increase is expected due to the FDA's clearance of newer pharmaceuticals on the market.

However, the current therapy choices' complexity, inefficiency, and high costs necessitate improved methods that would significantly extend the lives of multiple myeloma patients. With monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors to the present therapies array, the medicines market is likely to gain traction. The rising frequency of the disease, the growing older population, and the inefficiency of current medication are driving the market forward in the forecast era. Furthermore, patients' demand for supporting treatment, such as point-of-care technologies, and the safety profile and efficacy of monoclonal antibodies, are expected to widen the drug treatment options available to them.

However, this market has its limitations. The tiny target patient group is a restricting factor that will play a role throughout the forecast period. The market may become saturated as new mAbs are introduced one after another, resulting in revenue stability. In addition, the market expansion will be limited by the high cost of therapy and legal restrictions. In addition, the market's growth is hampered by the high cost of radiotherapeutic equipment and the chemotherapy process. The major market restraint is healthcare providers' growing cost-consciousness. The launch and subsequent label extensions of these pipeline treatments will incur high costs, potentially affecting patient uptake of these drugs.

This research report on the Europe multiple myeloma therapeutics market has been segmented and sub-segmented into the following categories

By Treatment Type:

  • Chemotherapy      
    • Anthracycline antibiotic
    • Alkylating agent
  • Targeted Therapy
    • Proteasome inhibitor

By Drug Type:

  • Corticosteroids     
    • Dexamethasone (Decadron)
    • Prednisone (Deltasone/Orasone)
  • Immunomodulatory agents             
    • Thalidomide (Thalomid)
    • Lenalidomide (Revlimid)
    • Arsenic trioxide (Trisenox)
    • Plerixafor (Mozobil)

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Large-scale companies worldwide are investing more in product R&D, which has been suitable for the market in recent years. Advances in ongoing clinical studies relating to the treatment of the condition will provide a tremendous opportunity for market players. France is the EU's largest market for Multiple Myeloma drugs, whereas Italy and Spain are expected to increase at the fastest rates. Because of significant companies and advantageous reimbursement regulations, the European market is likely to grow dramatically, and the percentage of drugs approved by the FDA right away. Rather than competing for market share, these new treatments will be combined to create more effective treatment regimens, pushing sales for one another. When patients relapse, a new treatment plan will be implemented. This indicates that there are significant revenue-generating opportunities within the anticipated period.


Companies playing a promising role in the Europe multiple myeloma therapeutics market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc., and Johnson and Johnson.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample